Eli Lilly (LLY) said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first head-to-head clinical trial. Eli Lilly stock edged higher in early trade while Novo Nordisk (NVO) was little changed.
Lilly's Zepbound reduced patients' weight by 20.2% after 72 weeks, or about 50 pounds. That's vs. 13.7%, or roughly 33 pounds, for Novo Nordisk drug Wegovy.
↑ XAlso, nearly 32% of Zepbound patients lost at least a one-fourth of their body weight vs. 16% for Wegovy takers.
The Eli Lilly-spurred study results are not a shock, given that separate studies have signaled that its Zepbound bests Novo's Wegovy on weight loss.
Zepbound's active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist. Wegovy's semaglutide is a GLP-1 receptor agonist.
In premarket trade, Eli Lilly stock rose 0.7%. Novo Nordisk stock was essentially flat.
YOU MAY ALSO LIKE:
Why This IBD Tool Simplifies The Search For Top Stocks
Catch The Next Big Winning Stock With MarketSurge
Best Growth Stocks To Buy And Watch
IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today
Futures Rise On Earnings; 3 Hot AI Stocks
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。